Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Schizophrenic symptoms and dietary intake of n-3 fatty acids.

Mellor JE, Laugharne JD, Peet M.

Schizophr Res. 1995 Dec;18(1):85-6. No abstract available.

PMID:
8929766
2.

omega-3 Fatty acid for schizophrenia.

Horrobin DF.

Am J Psychiatry. 2003 Jan;160(1):188-9; author reply 189. No abstract available.

PMID:
12505833
3.

Tardive dyskinesia and positive symptoms of schizophrenia.

White T, Brown KW, Woods JP.

Acta Psychiatr Scand. 1991 May;83(5):377-9.

PMID:
1677232
4.

Association of negative symptoms with tardive dyskinesia in schizophrenic patients.

Chiu H, Lau J, Lam L, Shum P.

Aust N Z J Psychiatry. 1993 Jun;27(2):228-32.

PMID:
8103320
5.
6.
7.

Clinical findings. Abnormalities of the mental state and movement disorder and their correlates.

Johnstone EC, Owens DG, Frith CD, Leary J.

Br J Psychiatry Suppl. 1991 Oct;(13):21-5, 44-6. No abstract available.

PMID:
1688117
8.

Movement disorders and psychological tests of frontal lobe function in schizophrenic patients.

Brown KW, White T, Palmer D.

Psychol Med. 1992 Feb;22(1):69-77.

PMID:
1349440
9.

Schizophrenia, tardive dyskinesia and essential fatty acids.

Vaddadi KS, Gilleard CJ, Soosai E, Polonowita AK, Gibson RA, Burrows GD.

Schizophr Res. 1996 Jul 5;20(3):287-94.

PMID:
8827855
10.
11.
12.

[Schizophrenic deficit syndrome and neurologic tolerance].

Verdoux H, Bourgeois M.

Encephale. 1996 Jun;22 Spec No 2:45-7. Review. French.

PMID:
8767042
13.

Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.

Liddle PF, Barnes TR, Speller J, Kibel D.

Br J Psychiatry. 1993 Dec;163:776-80.

PMID:
7905774
14.

Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.

Barnes TR, Liddle PF, Curson DA, Patel M.

Br J Psychiatry Suppl. 1989 Nov;(7):99-103. No abstract available.

PMID:
2575915
15.

[Exacerbation of catatonic symptoms in neuroleptic therapy].

Bräunig P, Krüger S, Höffler J.

Nervenarzt. 1995 May;66(5):379-82. German.

PMID:
7609820
16.

Targeting the effects of omega-3 and omega-6 fatty acid supplementation on schizophrenic spectrum disorders: role of neuroimaging.

Sota M, Allegri C, Cortesi M, Barale F, Politi P, Fusar-Poli P.

Med Hypotheses. 2007;69(2):466-7. Epub 2007 Feb 26. No abstract available.

PMID:
17324526
17.

T2 hyperintense foci on magnetic resonance images of schizophrenic patients and controls.

Bartzokis G, Garber HJ, Griswold VJ, Oldendorf WH, Mintz J, Marder SR.

Psychiatry Res. 1991 Dec;40(4):239-45.

PMID:
1811241
18.

Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.

Muscettola G, Barbato G, de Bartolomeis A, Monteleone P, Pickar D.

Psychiatry Res. 1990 Sep;33(3):259-67.

PMID:
2243901
19.

Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients.

Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R.

Schizophr Res. 1994 May;12(2):131-6.

PMID:
8043523
20.

Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.

Yamada K, Kanba S, Ohnishi K, Ashikari I, Yagi G, Asai M.

Biol Psychiatry. 1997 May 15;41(10):1062-4. No abstract available.

PMID:
9129786
Items per page

Supplemental Content

Write to the Help Desk